Skip to main content

Peer Review reports

From: Safety and effectiveness of eribulin in Japanese patients with soft tissue sarcoma including rare subtypes: a post-marketing observational study

Original Submission
7 Oct 2021 Submitted Original manuscript
22 Oct 2021 Reviewed Reviewer Report
7 Nov 2021 Reviewed Reviewer Report
25 Jan 2022 Author responded Author comments - Akira Kawai
Resubmission - Version 2
25 Jan 2022 Submitted Manuscript version 2
15 Feb 2022 Author responded Author comments - Akira Kawai
Resubmission - Version 3
15 Feb 2022 Submitted Manuscript version 3
28 Feb 2022 Author responded Author comments - Akira Kawai
Resubmission - Version 4
28 Feb 2022 Submitted Manuscript version 4
8 Mar 2022 Author responded Author comments - Akira Kawai
Resubmission - Version 5
8 Mar 2022 Submitted Manuscript version 5
10 Mar 2022 Reviewed Reviewer Report
13 Mar 2022 Reviewed Reviewer Report
25 Mar 2022 Author responded Author comments - Akira Kawai
Resubmission - Version 6
25 Mar 2022 Submitted Manuscript version 6
30 Mar 2022 Reviewed Reviewer Report
2 Apr 2022 Reviewed Reviewer Report
Resubmission - Version 7
Submitted Manuscript version 7
Publishing
11 Apr 2022 Editorially accepted
11 May 2022 Article published 10.1186/s12885-022-09527-y

You can find further information about peer review here.

Back to article page